Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab

Journal for ImmunoTherapy of Cancer

Volumn 6, Issue 1, 2018, Pages

  Acero Brand, Fanny Zulay ^a   Suter, Nicolas ^a   Adam, Jean Philippe ^b   Faulques, Bernard ^b   Maietta, Antonio ^b   Soulières, Denis ^b   Blais, Normand ^b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Esophagitis; Immune related adverse event; Mucositis; Pembrolizumab

Indexed keywords

CISPLATIN; METHYLPREDNISOLONE; PEMBROLIZUMAB; PREDNISONE; ANTIINFLAMMATORY AGENT; GLUCOCORTICOID; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CASE REPORT; CLINICAL ARTICLE; DYSPHAGIA; FOLLOW UP; GASTROSCOPY; GRANULATION TISSUE; HISTOLOGY; HUMAN; HUMAN TISSUE; LARYNX CARCINOMA; LUNG METASTASIS; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; ORAL MUCOSITIS; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; ULCERATIVE ESOPHAGITIS; ESOPHAGUS MUCOSA; HEAD AND NECK TUMOR; LARYNX; MOUTH MUCOSA; MUCOSA INFLAMMATION; PATHOLOGY;

AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; ESOPHAGEAL MUCOSA; GLUCOCORTICOIDS; HEAD AND NECK NEOPLASMS; HUMANS; LARYNX; MALE; MOUTH MUCOSA; MUCOSITIS; PREDNISONE; PROGRAMMED CELL DEATH 1 RECEPTOR; SQUAMOUS CELL CARCINOMA OF HEAD AND NECK;

EID: 85043992921     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/s40425-018-0332-z     Document Type: Article

References (20)

1. Bauml J, Seiwert TY, Pfister DG, et al. Pembrolizumab for platinum- and Cetuximab-refractory head and neck cancer: results from a single-arm, phase II study. J Clin Oncol. 2017;35:1542-9.
2. Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17:956-65.
3. Zander T, Aebi S, Rast AC, et al. Response to Pembrolizumab in a patient with relapsing Thymoma. J Thorac Oncol. 2016;11:e147-9.
4. Boike J, Dejulio T. Severe esophagitis and gastritis from Nivolumab therapy. ACG Case Rep J. 2017;4:e57.
5. Ribas A. Tumor immunotherapy directed at PD-1. N Engl J Med. 2012;366:2517-9.
6. Chow LQ, Haddad R, Gupta S, et al. Antitumor activity of Pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol. 2016;34:3838-45.
7. Eigentler TK, Hassel JC, Berking C, et al. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev. 2016;45:7-18.
8. Hofmann L, Forschner A, Loquai C, et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer. 2016;60:190-209.
9. Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015;26:2375-91.
10. Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32:1020-30.
11. Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856-67.
12. ClinicalTrials.gov.Protocol CA209153. https://clinicaltrials.gov/ct2/show/study/NCT02066636. Accessed 20 Dec 2016.
13. ClinicalTrials.gov. Protocol CA209-214. https://clinicaltrials.gov/ct2/show/NCT02231749. Accessed 20 Dec 2016.
14. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540-50.
15. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-45.
16. Hart PA, Romano RC, Moreira RK, et al. Esophagitis Dissecans Superficialis: clinical, endoscopic, and histologic features. Dig Dis Sci. 2015;60:2049-57.
17. Moawad FJ, Appleman HD. Sloughing esophagitis: a spectacular histologic and endoscopic disease without a uniform clinical correlation. Ann N Y Acad Sci. 2016;1380:178-82.
18. Pollack MH, Betof A, Dearden H, et al. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Ann Oncol. 2018;29:250-5.
19. Weber JS, Postow M, Lao CD, Schadendorf D. Management of Adverse Events Following Treatment with anti-programmed Death-1 agents. Oncologist. 2016;21:1230-40.
20. Bergqvist V, Hertervig E, Gedeon P, et al. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. Cancer Immunol Immunother. 2017;66:581-92.